{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T16:20:49Z","timestamp":1794932449743,"version":"4.9.1"},"reference-count":12,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T00:00:00Z","timestamp":1788307200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.vaccine.2026.129095","type":"journal-article","created":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T21:27:26Z","timestamp":1787866046000},"page":"129095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines"],"prefix":"10.1016","volume":"91","author":[{"given":"Muhammad Atiqul","family":"Islam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syeda Mahjabeen","family":"Zehra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaubina","family":"Kazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salman","family":"Ather","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabeena","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rehnuma Tabassum","family":"Timu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneeta","family":"Hotwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Sharif","family":"Hossain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aimon","family":"Tahir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weixiao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasif Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali Faisal","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2026.129095_bb0005","author":"Ritchie"},{"key":"10.1016\/j.vaccine.2026.129095_bb0010","doi-asserted-by":"crossref","first-page":"934","DOI":"10.15585\/mmwr.mm6535a3","article-title":"Cessation of trivalent oral poliovirus vaccine and introduction of inactivated poliovirus vaccine \u2013 worldwide","volume":"65","author":"Initiative ISMGotGPE","year":"2016","journal-title":"Morb Mortal Wkly Rep"},{"issue":"suppl_1","key":"10.1016\/j.vaccine.2026.129095_bb0015","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiu128","article-title":"Affordable inactivated poliovirus vaccine: strategies and progress","volume":"2010","author":"Okayasu","year":"2014","journal-title":"J Infect Dis"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129095_bb0020","first-page":"819","article-title":"The polio endgame\u2014scientific insightsBulletin of the world health Organization","volume":"93","author":"PD M","year":"2015","journal-title":"Bull World Health Organ"},{"issue":"12","key":"10.1016\/j.vaccine.2026.129095_bb0025","first-page":"145","article-title":"Polio vaccines: WHO position paper, March 2016","volume":"91","author":"Organization WH","year":"2016","journal-title":"Wkly Epidemiol Rec"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129095_bb0035","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1093\/infdis\/jiy736","article-title":"Immunogenicity and safety of a Sabin strain-based inactivated polio vaccine: a phase 3 clinical trial","volume":"220","author":"Hu","year":"2019","journal-title":"J Infect Dis"},{"issue":"10","key":"10.1016\/j.vaccine.2026.129095_bb0040","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofz380","volume":"6","author":"Hu","year":"2019","journal-title":"Open Forum Infect Dis"},{"issue":"45","key":"10.1016\/j.vaccine.2026.129095_bb0045","doi-asserted-by":"crossref","DOI":"10.1016\/j.vaccine.2018.09.023","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, dose-finding trial","volume":"36","author":"Chu","year":"2018","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vaccine.2026.129095_bb0050","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1093\/infdis\/jiaa770","article-title":"Safety and immunogenicity of a new inactivated polio vaccine made from Sabin strains: a randomized, double-blind, active-controlled, phase 2\/3 seamless study","volume":"226","author":"Capeding","year":"2022","journal-title":"J Infect Dis"},{"issue":"1","key":"10.1016\/j.vaccine.2026.129095_bb0055","doi-asserted-by":"crossref","DOI":"10.1038\/s41541-024-00828-w","article-title":"A phase III randomized-controlled study of safety and immunogenicity of DTwP-HepB-IPV-Hib vaccine (HEXASIIL\u00ae) in infants","volume":"9","author":"Sharma","year":"2014","journal-title":"NPJ Vaccines"},{"issue":"25","key":"10.1016\/j.vaccine.2026.129095_bb0060","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1016\/j.vaccine.2007.11.096","article-title":"Immunogenicity, reactogenicity, and safety of a seven-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a fully liquid DTPa-IPV-HBV-Hib combination vaccine in healthy infants","volume":"26","author":"Olivier","year":"2008","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2026.129095_bb0065","doi-asserted-by":"crossref","unstructured":"Sanchez L RS, Kosalaraksa P, et al. Immunogenicity and safety of a hexavalent DTwP-IPV-HB-PRPT vaccine versus separate DTwP-HB-PRPT, bOPV, and IPV vaccines administered at 2, 4, 6 months of age concomitantly with rotavirus and pneumococcal conjugate vaccines in healthy infants in Thailand. Pediatr Infect Dis J: 42; (8): 711\u2013718.","DOI":"10.1097\/INF.0000000000003975"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009047?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X26009047?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T15:52:15Z","timestamp":1794930735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X26009047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":12,"alternative-id":["S0264410X26009047"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129095","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multi-center, open-labelled, randomized controlled extended phase III non-inferiority clinical trial to evaluate the immunogenicity and tolerability of poliomyelitis vaccine (Vero cells), inactivated, Sabin strains administered with or without routine infant vaccines","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2026.129095","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129095"}}